Jose Baselga, MD, PhD: BOLERO-2 Findings Confirm Efficacy of Everolimus Plus Exemestane

 

Dr. Jose Baselga discusses the exciting data for the HER2-negative breast cancer patient — the BOLERO-2 trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium.

Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard Medical School.

 

The Group Room at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium was made possible by support from:

• Jose Baselga
• SABCS 2011

Comments